Dr. Vanbiervliet, Market Intelligence and Business Development Manager, Infectious Diseases, at Debiopharm, a biopharmaceutical company in Lausanne Switzerland. Passionate about identifying new solutions in response to global infectious disease threats, she is leading market insights generation and also business development activities for the anti-infectives programs which include the pathogen-specific FabI inhibitors afabicin, Debio 1453 and Debio 1454. Having joined Debiopharm in 2008, her collaborative work with medical, clinical and scientific teams supported early stage and clinical development of programs mainly for antivirals against HCV and antibiotics. Notably, she contributed to the successful acquisition of afabicin and related technology that led to the discovery of Debio 1453 and Debio 1454. Dr. Vanbiervliet graduated from the French engineering school ENSAR in Rennes. She holds a PhD degree in Virology from University Rennes 1 and ENSAR.